State Street SPDR S&P Biotech ETF
XBI
XBI
777 hedge funds and large institutions have $9.75B invested in State Street SPDR S&P Biotech ETF in 2024 Q1 according to their latest regulatory filings, with 129 funds opening new positions, 255 increasing their positions, 233 reducing their positions, and 81 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
more funds holding
Funds holding: →
9% more repeat investments, than reductions
Existing positions increased: 255 | Existing positions reduced: 233
0% more funds holding in top 10
Funds holding in top 10: 23 → 23 (0)
43% less call options, than puts
Call options by funds: $2.25B | Put options by funds: $3.97B
Holders
777
Holding in Top 10
23
Calls
$2.25B
Puts
$3.97B
Top Buyers
| 1 | +$447M | |
| 2 | +$391M | |
| 3 | +$356M | |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$280M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$131M |
Top Sellers
| 1 | -$326M | |
| 2 | -$149M | |
| 3 | -$66.8M | |
| 4 |
Millennium Management
New York
|
-$65.6M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$57.8M |